Results 81 to 90 of about 665 (169)

Risk of Cancer in People With HIV Experiencing Varying Degrees of Immune Recovery With Sustained Virological Suppression on Antiretroviral Treatment for More Than 2 Years: An International, Multicenter, Observational Cohort. [PDF]

Clin Infect Dis
Han WM, Ryom L, Sabin CA, Greenberg L, Cavassini M, Egle A, Duvivier C, Wit FWNM, Mussini C, d'Arminio Monforte A, Castagna A, Miro JM, van der Valk M, Bonnet F, Pradier C, Skocic M, Matulionyte R, Stöckle M, Jaschinski N, Timiryasova A, Tallada J, Rogatto FP, Vannappagari V, Young LA, Lundgren JD, Petoumenos K, Hoy JF.   +26 more
europepmc   +1 more source

SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio. [PDF]

Vaccines (Basel), 2023
Vergori A, Tavelli A, Matusali G, Azzini AM, Augello M, Mazzotta V, Pellicanò GF, Costantini A, Cascio A, De Vito A, Marconi L, Righi E, Sartor A, Pinnetti C, Maggi F, Bai F, Lanini S, Piconi S, Levy Hara G, Marchetti G, Giannella M, Tacconelli E, d'Arminio Monforte A, Antinori A, Cozzi-Lepri A, On Behalf Of The Vax-Icona-Orchestra Study.   +25 more
europepmc   +1 more source

Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for hepatitis C virus in people with HIV. [PDF]

AIDS
Chalouni M, Torgersen J, Rentsch CT, Van Santen DK, Jarrin I, Klein MB, Young J, Gill MJ, Epstein RL, Linas B, Zangerle R, Surial B, Nemeth J, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte AD, Puoti M, Logan RW, Rein SM, Miro JM, Berenguer J, Hernán MA, Lodi S.   +25 more
europepmc   +1 more source

Severe viral rash progression prediction and surveillance early warning based on local-global attention and temporal convolutional network. [PDF]

Front Public Health
Li S, Li Z, Mo Y, Qiu B, Ning Z, Ren J, Wang Z, He X.   +7 more
europepmc   +1 more source

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. [PDF]

Lancet HIV, 2023
Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, Bellecave P, van Sighem A, Stecher M, d'Arminio Monforte A, Gill MJ, Sabin CA, Maartens G, Günthard HF, Sterne JAC, Lessells R, Egger M, Kouyos RD.   +17 more
europepmc   +1 more source

Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic. [PDF]

Viruses
Vergori A, Gianotti N, Tavelli A, Tincati C, Giacomelli A, Matteini E, Lapadula G, Taramasso L, Sarmati L, D'Arminio Monforte A, Antinori A, Cozzi-Lepri A, On Behalf Of The Icona Foundation Study, ICONA Foundation Study.   +13 more
europepmc   +1 more source

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view. [PDF]

J Antimicrob Chemother
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A, ICONA Foundation Study group.   +14 more
europepmc   +1 more source

Icona Vs Quadro. Il dualismo visuale dell'Ekphrasis dostoevskiana [PDF]

Kaiak, 2016
Antonina Nocera
doaj  

Use of Preventive Measures for Cardiovascular Disease in People With HIV. [PDF]

Open Forum Infect Dis
Jaschinski N, Neesgaard B, Wit F, Van der Valk M, Kowalska J, Ridolfo AL, Günthard HF, Stöckle M, Wallner E, Nowak P, Castagna A, d'Arminio Monforte A, Petoumenos K, Hoy JF, Hosein S, Lundgren J, Garges H, Rogatto F, Young L, Peters L, Mocroft A, Ryom L, RESPOND Study Group .   +22 more
europepmc   +1 more source

Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona). [PDF]

EBioMedicine
Mazzotta V, Nozza S, Lanini S, Moschese D, Tavelli A, Rossotti R, Fusco FM, Biasioli L, Matusali G, Raccagni AR, Mileto D, Maci C, Lapadula G, Di Biagio A, Pipitò L, Tamburrini E, Monforte AD, Castagna A, Antinori A, mpox-Icona study group.   +19 more
europepmc   +1 more source